MedPage Today November 11, 2024
Sentynl Therapeutics, Inc.

About Dr. Wendy Chung and the GUARDIAN Study

Hello, I’m Dr. Liza Squires, a Medical Consultant at Sentynl Therapeutics, a U.S.-based biopharmaceutical company focused on rare disease.

Today, I’m here with Dr. Wendy Chung, a clinical and molecular geneticist and Chief of the Department of Pediatrics at Boston Children’s Hospital and Harvard Medical School. Today, we’ll discuss the importance of advancing newborn screening with whole genome sequencing, and how healthcare providers can advocate for this important advancement.

Dr. Chung, thank you for your time. Could you share a bit about your background and work in newborn screening and genetics?

Dr. Chung

Thanks Liza, it’s good to be here. For the past 35 years, I’ve dedicated my career to genetics and...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

 
Topics: Conferences / Podcast, Pharma / Biotech, Precision Medicine, Survey / Study, Trends
JPM 2026: Genoa Ventures’ Jenny Rooke on Next-Gen Clinical Assessment Tools
From Early Detection to Targeted Therapy: How AI is Reframing Precision Medicine
How Precision Medicine and AI are Evolving: An MD Anderson Perspective
Bringing Precision Medicine Into the Home
Inside the Virtual Cell: New Depths for Precision Medicine

Share Article